Adult hearts have inherently limited regenerative capabilities, such that injury results in lasting damage. The situation is different in neonatal mouse hearts, however, where a new study reveals a role for the immunomodulatory PD-1–PD-L1 pathway in regulating regeneration after injury.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Han, C. et al. Cell Res. 25, 1137–1151 (2015).
Tzahor, E. & Dimmeler, S. Science 377, eabm4443 (2022).
Aurora, A. B. et al. J. Clin. Invest. 124, 1382–1392 (2014).
Lavine, K. J. et al. Proc. Natl Acad. Sci. USA 111, 16029–16034 (2014).
Tan, Y., Duan, X., Wang, B., Liu, X. & Zhan, Z. Npj Regen. Med. 8, 7 (2023).
Dolejsi, T. et al. Eur. Heart J. 43, 2698–2709 (2022).
Li, J. et al. Theranostics 10, 8018–8035 (2020).
Aguilar, S. C. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-024-00447-7 (2024).
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L. & Kitsis, R. N. J. Clin. Invest. 131, e145186 (2021).
Tuttle, J. et al. N. Engl. J. Med. 388, 1853–1862 (2023).
Frangogiannis, N. G. Circ. Res. 110, 159–173 (2012).
Acknowledgements
J.M. is supported by National Institutes of Health grants R01HL141466, R01HL155990, R01HL156021, R01HL160688 and R01HL170038. G.N.H. is supported by National Institutes of Health grants R01 HL157280 and R01 HL138456, Tobacco-Related Disease Research Program award P0558275, and American Heart Association Established Investigator award 23EIA1039425. J.Q. is supported by UCSF Catalyst Award 2024 and AHA’s Second Century Early Faculty Independence Award 24SCEFIA1246915.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M. has provided consulting or advisory roles for Pfizer, Novartis, Bristol-Myers Squibb, Deciphera, Takeda, AstraZeneca, Regeneron, Myovant, Kurome Therapeutics, Kiniksa Pharmaceuticals, Daiichi Sankyo, BeiGene, IQVIA, AskBio, Bitterroot Bio, Repare Therapeutics and Cytokinetics. J.M. is a co-inventor of a patent related to the use of abatacept in the treatment of ICI-myocarditis. J.Q. and G.N.H. declare no competing interests.
Rights and permissions
About this article
Cite this article
Qin, J., Huang, G.N. & Moslehi, J. PD-1–PD-L1 immunomodulatory pathway regulates cardiac regeneration. Nat Cardiovasc Res 3, 410–411 (2024). https://doi.org/10.1038/s44161-024-00461-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-024-00461-9